Burrill & Company identified more than $2.6bn in expected funding through nine healthcare initiatives announced since the end of February to end-March.
A host of new initiatives focused on funding translational research and early-stage companies brought together the public and private sector, particularly with the goal of building life sciences centers in specific locations. In all, Burrill & Company identified more than $2.6bn in expected funding through nine initiatives announced since the end of February to end-March.
The largest of these efforts, a $760m partnership between Russia’s Rusnano and the US venture capital firm Domain Associates, will invest in emerging life sciences…
